Sign inCreate account

Report workspace

Add to folder
NCT05850871UNKNOWNanonymous

Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes

Sponsor

Source record

Qianfoshan Hospital

Phase

Source record

Not Applicable

Modality

AI-normalized

small molecule

Target

AI-normalized

Ceftazidime-avibactam (CAZ-AVI) and Aztreonam (ATM) targeting Metallo-β-lactamases (MBL) producing Enterobacterales; CRISPR/Cas9 technology for gene editing of drug resistance and virulence genes.

Indication / condition

AI-normalized

Carbapenem-Resistant Enterobacteriaceae Infection

Intervention

Source record

CAZ/AVI plus Aztreonam, Conventional treatment

Source & freshness

Source record

NCT ID

NCT05850871

Original source

ClinicalTrials.gov

Source last updated

May 09, 2023

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05850871

Title

Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes

Sponsor

Qianfoshan Hospital

Status

UNKNOWN

Phase

Not Applicable

Condition raw

Carbapenem-Resistant Enterobacteriaceae Infection

Condition normalized

Carbapenem-Resistant Enterobacteriaceae Infection

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Ceftazidime-avibactam (CAZ-AVI) and Aztreonam (ATM) targeting Metallo-β-lactamases (MBL) producing Enterobacterales; CRISPR/Cas9 technology for gene editing of drug resistance and virulence genes.

Target normalized

Ceftazidime-avibactam (CAZ-AVI) and Aztreonam (ATM) targeting Metallo-β-lactamases (MBL) producing Enterobacterales; CRISPR/Cas9 technology for gene editing of drug resistance and virulence genes.

Interventions

CAZ/AVI plus Aztreonam, Conventional treatment

Public preview

Source record

The trial, sponsored by Qianfoshan Hospital, aims to evaluate the efficacy of CAZ-AVI in combination with ATM against MBL-producing Enterobacterales, a significant concern in antibiotic resistance. The market for antibiotics targeting resistant bacteria is expanding due to rising incidences of multi-drug resistant infections. Successful outcomes could position CAZ-AVI and ATM as a preferred treatment option, potentially leading to increased market share in the antibiotic sector. The incorporation of CRISPR/Cas9 technology may also open avenues for novel therapeutic approaches, enhancing the asset's attractiveness to investors and partners. However, the competitive landscape includes established antibiotics and emerging therapies, necessitating thorough diligence on market positioning and regulatory pathways.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT05850871

Status

UNKNOWN

Phase

Not Applicable

Sponsor

Qianfoshan Hospital

Executive brief

Investment-Ready Snapshot

The trial, sponsored by Qianfoshan Hospital, aims to evaluate the efficacy of CAZ-AVI in combination with ATM against MBL-producing Enterobacterales, a significant concern in antibiotic resistance. The market for antibiotics targeting resistant bacteria is expanding due to rising incidences of multi-drug resistant infections. Successful outcomes could position CAZ-AVI and ATM as a preferred treatment option, potentially leading to increased market share in the antibiotic sector. The incorporation of CRISPR/Cas9 technology may also open avenues for novel therapeutic approaches, enhancing the asset's attractiveness to investors and partners. However, the competitive landscape includes established antibiotics and emerging therapies, necessitating thorough diligence on market positioning and regulatory pathways.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 09, 2023
Internal syncJun 13, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05850871

Indication

Carbapenem-Resistant Enterobacteriaceae Infection

Modality

small molecule

Target

Ceftazidime-avibactam (CAZ-AVI) and Aztreonam (ATM) targeting Metallo-β-lactamases (MBL) producing Enterobacterales; CRISPR/Cas9 technology for gene editing of drug resistance and virulence genes.

Intervention

CAZ/AVI plus Aztreonam, Conventional treatment

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.